Latest From Biotech Now

Successful Public-Private Partnerships

According to BayBio, biomedical companies that can harness the power of patient groups will get medicines, devices and diagnostics to market faster, cheaper and smarter, helping patients and rewarding investors. Gail Maderis, ‎President & CEO at BayBio, debuted their preliminary whitepaper entitled “Successful Public-Private Partnerships” today at the 2013 BIO Investor Forum. BayBio surveyed nearly 100 biotech and foundation CEOs, vice presidents of research, directors of patient advocacy and others across the United States. Following Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

JOBS Act Deconstructed: Regulation A

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act.  BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage. In a nutshell: The JOBS Act directs the SEC to create a new class of securities modeled after those eligible for the existing exemption under SEC Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Investor Forum Kicks Off Amid Industry Optimism

San Francisco skyline

Today, the BIO Investor Forum kicks off in San Francisco, Calif. BioWorld’s Catherine Shaffer paints a positive picture of the industry (subscription required) highlighting the strong IPO activity and heightened interest in the sector among investors. The conference reflects the upward momentum of the industry with increased expected attendance among both companies and investors. The JOBS Act is widely viewed as the underlying reason for these positive trends in the industry as the law helped Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

Fighting Blindness through Sound Investments in Research


Since 1971, the Foundation Fighting Blindness has raised more than half a billion dollars in support of its mission to put an end to retinal diseases. Those diseases affect more than 10 million Americans at risk of vision impairment, legal blindness or total blindness. Because age-related macular degeneration (AMD), one of the diseases we target, is the leading cause of blindness in people over 55, and because the Baby Boomer population is aging, that number Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO Investor Forum Interview with Regado Biosciences


BIO is very excited to be hosting the BIO Investor Forum next week in San Francisco. The BIO One-on-One Partnering System has already scheduled over 640 meetings, which is a 50% increase over last year. Investor and company registration is also trending higher, including the number of presenting companies. The One-on-One Compass has been profiling these companies slated to present at the conference, and recently spoke to the CEO of Regado Biosciences, David Mazzo. Please Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,